INTERIM REPORT JANUARY - SEPTEMBER 2004
INTERIM REPORT JANUARY - SEPTEMBER 2004 · Turnover rose by 37 percent during the first nine months of the year to SEK 585.5 (427.8) million. · Operating income amounted to SEK 365.5 (452) million. · Operating income adjusted for one-time revenues and one-time expenses amounted to SEK 34.6 (-10.2) million for the nine-month period. · Net income after tax amounted to SEK 316.0 (457.1) million for the period. · Earnings per share amounted to SEK 12.74 (18.42). · Continued good growth for Esthetics and Hospital Healthcare. · A first payment of USD 30 million concerning RESTYLANE SubQ in the USA and Canada was received from Medicis in July. · The one-year study into stress urinary incontinence is creating increased interest for treatment with ZUIDEX. · DUROLANE has been approved for reimbursement through the social insurance system in France. Queries should be addressed to: Bengt Ågerup, President and CEO, Tel: +(0)70-974 90 25 Erika Kjellberg Eriksson, Vice President and CFO, Tel: +(0)70-974 90 20 Anne Rhenman, Director Investor Relations and Corporate Communications, Tel: +(0)70-974 90 15 Q-Med is a rapidly growing and profitable biotechnology/medical device company that develops, produces and markets medical implants. All products are based on the company's patented NASHA technology - Non-Animal Stabilized Hyaluronic Acid. The products covered by the RESTYLANE trademark are used for the filling out of lips and facial wrinkles and for facial contouring and today account for the majority of sales. RESTYLANE is sold in over 70 countries and has been approved in the USA. DUROLANE, Q-Med's product for the treatment of osteoarthritis of the hip and knee joints, has been approved in Europe since May 2001. DEFLUX is a product which has been approved in Europe and the USA for the treatment of vesicoureteral reflux (malformation of the urinary bladder) in children. ZUIDEX for the treatment of stress urinary incontinence in women has been sold in Europe since July 2002. Q-Med today has approximately 500 employees, with approximately 320 at the company's production facility and head office in Uppsala. The Q-Med share is listed on the Attract 40 list of the Stockholm Stock Exchange. ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/11/03/20041103BIT20060/wkr0001.pdf The full report